Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 23, 2026 - P1/2 | N=43 | Not yet recruiting | Sponsor: VA Office of Research and Development
IO biomarker • New P1/2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CRP • IL6 • PD-L1 • RET • ROS1
|